The INTEGRATE Study: Integrated Pharmacogenetics, TDM and Active Pharmacovigilance as Innovative Tools for the Optimisation and Appropriateness of Drug Therapy

Last updated: March 10, 2026
Sponsor: Direzione centrale salute, politiche sociali e disabilità
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

N/A

Treatment

Pharmacogenetics, TDM and MedReview

Clinical Study ID

NCT06822959
CRO-2022-14
  • All Genders

Study Summary

The primary goal of this observational study is to evaluate the feasibility of implementing a multidisciplinary approach based on pharmacogenetics, TDM (Therapeutic Drug Monitoring) and MedReview into the clinical practice in order to optimize the appropriateness of drugs prescription and to minimise the risk of Adverse Drug Reactions (ADRs) in adult cancer patients and in pediatric patients affected by chronic inflammatory diseases. This approach of active pharmacovigilance will also allow a better definition of the causality assessment of ADRs through the direct implementation of data quality in the reporting forms. The study may therefore constitute an example of an approach for both the prevention of ADRs and the optimization of drug use, and for the integration of pharmacogenetics, TDM, and the MedReview data into the National Pharmacovigilance Reports for an improved and innovative evaluation of adverse events, aiming at the implementation of this approach in the regional context.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients who are candidates for therapy with:

  • Abemaciclib,

  • Palbociclib,

  • Ribociclib,

  • Letrozole,

  • Tamoxifen,

  • Olaparib,

  • Niraparib,

  • Rucaparib,

  • Imatinib,

  • Sunitinib,

  • Sorafenib,

  • Regorafenib,

  • Lenvatinib,

  • Irinotecan,

  • Capecitabine,

  • 5-Fluorouracil,

  • Infliximab,

  • Cyclophosphamide,

  • Methotrexate,

  • Adalimumab,

  • 6-Mercaptopurine/Azathioprine

Study Design

Total Participants: 450
Treatment Group(s): 1
Primary Treatment: Pharmacogenetics, TDM and MedReview
Phase:
Study Start date:
June 10, 2022
Estimated Completion Date:
October 31, 2026

Study Description

Primary aim of the study:

To implement the use of pharmacogenetics, TDM, and MedReview at the regional level supporting their utility through an observational approach to assess the effects of these innovative methods, already active in IRCCS, for the optimization of appropriate drug use and minimization of ADR risk in adult and pediatric oncology patients, as well as pediatric patients with chronic inflammatory diseases. Specifically, the aim is to evaluate the incidence of ADRs in patients treated based on pharmacogenetics, TDM, and MedReview compared to historical cases treated according to the standard of care before the implementation of the proposed innovative methodologies.

Secondary aims of the study:

  1. To evaluate the "Causality Assessment" between ADR and drug based on the enhanced data quality deriving from the integration of pharmacogenetics, TDM and MedReview into the Pharmacovigilance report.

  2. To propose the systematic integration of the results related to pharmacogenetics, TDM, and MedReview within the existing fields of the current ADR reporting form. This aims to develop a proposal for updating AIFA procedures related to the inclusion of this type of evidence-based information in the National Pharmacovigilance Network (RNF), with a potential update of the reporting form.

Connect with a study center

  • Centro di Riferimento Oncologico di Aviano (CRO)

    Aviano, Pordenone 33081
    Italy

    Site Not Available

  • IRCCS materno infantile Burlo Garofolo di Trieste

    Trieste, Trieste 34137
    Italy

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.